Deprescribing Program for Dementia and Diabetes
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it focuses on reducing certain diabetes medications that have a high risk of causing low blood sugar. It's best to discuss with the trial team or your doctor.
What data supports the effectiveness of the treatment STRIDE for dementia and diabetes?
Is the deprescribing program for dementia and diabetes safe for humans?
How is the STRIDE treatment different from other treatments for dementia and diabetes?
The STRIDE treatment is unique because it focuses on deprescribing, which means reducing or stopping medications that may be unnecessary or harmful, especially for older adults with dementia who often take multiple medications. This approach aims to decrease the risk of adverse outcomes by minimizing the burden of unnecessary medication use.310111213
What is the purpose of this trial?
Objectives To 1) examine the ability of the STRIDE (Simplification of Treatment Regimens and Individualized Diabetes Education) educational program to increase deprescribing of high hypoglycemia risk glucose-lowering medications (HRMs) among long term care facility (LTCF) residents with ADRD, 2) assess key implementation constructs (secondary outcomes) of the STRIDE program, including acceptability, appropriateness, and feasibility, and 3) validate the primary HRM use outcome measure.
Research Team
Medha Munshi, MD
Principal Investigator
Joslin Diabetes Center
Eligibility Criteria
This trial is for clinical staff at long-term care facilities, including doctors, physician assistants, nurse practitioners, and clinical pharmacists. They must have participated in the STRIDE program aimed at educating on deprescribing diabetes medication for residents with Alzheimer's.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Implementation of the STRIDE educational program to increase deprescribing of high hypoglycemia risk glucose-lowering medications among LTCF residents with ADRD
Follow-up
Participants are monitored for changes in HRM use and assessed for acceptability, appropriateness, and feasibility of the STRIDE program
Treatment Details
Interventions
- STRIDE
Find a Clinic Near You
Who Is Running the Clinical Trial?
Joslin Diabetes Center
Lead Sponsor
Brown University
Collaborator
Theoria Medical
Collaborator